T1	PROC 73 86	Inmunoterapia
#1	AnnotatorNotes T1	C0021083; Immunotherapy; Therapeutic or Preventive Procedure
T2	PROC 91 104	Quimioterapia
#2	AnnotatorNotes T2	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T3	DISO 122 175	adenocarcinoma gástrico o de la unión gastroesofágica
T4	ANAT 154 175	unión gastroesofágica
#3	AnnotatorNotes T4	C0014871; Esophagogastric Junction; Body Space or Junction
T5	PROC 196 240	Ensayo clínico fase 2, aleatorizado, abierto
T6	CHEM 273 282	Nivolumab
#4	AnnotatorNotes T6	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	PROC 302 315	quimioterapia
#5	AnnotatorNotes T7	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T8	CHEM 325 334	Nivolumab
#6	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	PROC 354 367	quimioterapia
#7	AnnotatorNotes T9	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T10	PROC 373 401	tratamiento de primera línea
#8	AnnotatorNotes T10	C1708063; First line treatment; Therapeutic or Preventive Procedure
T11	DISO 419 472	adenocarcinoma gástrico o de la unión gastroesofágica
T12	ANAT 451 472	unión gastroesofágica
#9	AnnotatorNotes T12	C0014871; Esophagogastric Junction; Body Space or Junction
T13	DISO 494 539	Cáncer gástrico o de la unión gastroesofágica
T14	ANAT 518 539	unión gastroesofágica
#10	AnnotatorNotes T14	C0014871; Esophagogastric Junction; Body Space or Junction
T15	DISO 564 617	Adenocarcinoma gástrico o de la unión gastroesofágica
T16	ANAT 596 617	unión gastroesofágica
#11	AnnotatorNotes T16	C0014871; Esophagogastric Junction; Body Space or Junction
T17	PROC 733 744	Diagnóstico
#12	AnnotatorNotes T17	C0011900; Diagnosis; Diagnostic Procedure
T18	DISO 789 791	CG
T19	ANAT 815 818	UGE
T20	PROC 871 892	tratamiento sistémico
T21	CHEM 911 931	inhibidores de HER 2
T22	PROC 951 967	terapia primaria
#13	AnnotatorNotes T22	C1708063; First line treatment; Therapeutic or Preventive Procedure
T23	DISO 973 975	CG
T24	DISO 855 866	metastásico
#14	AnnotatorNotes T24	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T25	ANAT 999 1002	UGE
T26	PROC 1111 1115	HER2
#15	AnnotatorNotes T26	C5189164; HER2 in tissue by immunoassay; Laboratory Procedure
T27	ANAT 1170 1194	sistema nervioso central
#16	AnnotatorNotes T27	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T28	ANAT 1196 1199	SNC
#17	AnnotatorNotes T28	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T29	ANAT 137 145	gástrico
#18	AnnotatorNotes T29	C0038351; Stomach; Body Part, Organ, or Organ Component | C1278920; Entire stomach; Body Part, Organ, or Organ Component | C3714551; Stomach structure; Body Part, Organ, or Organ Component
T30	ANAT 434 442	gástrico
#19	AnnotatorNotes T30	C0038351; Stomach; Body Part, Organ, or Organ Component | C1278920; Entire stomach; Body Part, Organ, or Organ Component | C3714551; Stomach structure; Body Part, Organ, or Organ Component
T31	ANAT 501 509	gástrico
#20	AnnotatorNotes T31	C0038351; Stomach; Body Part, Organ, or Organ Component | C1278920; Entire stomach; Body Part, Organ, or Organ Component | C3714551; Stomach structure; Body Part, Organ, or Organ Component
T32	ANAT 579 587	gástrico
#21	AnnotatorNotes T32	C0038351; Stomach; Body Part, Organ, or Organ Component | C1278920; Entire stomach; Body Part, Organ, or Organ Component | C3714551; Stomach structure; Body Part, Organ, or Organ Component
T33	DISO 794 818	adenocarcinoma de la UGE
T34	DISO 1131 1141	metástasis
#22	AnnotatorNotes T34	C0027627; Neoplasm Metastasis; Neoplastic Process | C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T35	DISO 1202 1227	Enfermedad cardiovascular
#23	AnnotatorNotes T35	C0007222; Cardiovascular Diseases; Disease or Syndrome
T36	ANAT 1213 1227	cardiovascular
#24	AnnotatorNotes T36	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T37	CHEM 245 255	Relatlimab
#25	AnnotatorNotes T37	C4724799; Relatlimab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T38	CHEM 257 267	anti-LAG-3
T39	PROC 1155 1163	tratadas
#26	AnnotatorNotes T39	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T40	DISO 978 1002	adenocarcinoma de la UGE
T41	DISO 1039 1050	metastásico
#27	AnnotatorNotes T41	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T42	Date 13 17	2018
T43	LIVB 108 117	pacientes
#28	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	LIVB 405 414	pacientes
#29	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T48	Neg_cue 1152 1154	no
T45	Neg_cue 868 870	No
T46	PROC 660 676	estado funcional
#30	AnnotatorNotes T46	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T47	LIVB 1078 1087	Pacientes
#31	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T49	LIVB 1117 1126	Pacientes
#32	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	PROC 756 785	histológica o citológicamente
#33	AnnotatorNotes T50	C1305671; Cytology procedure; Laboratory Procedure | C0344441; Histology Procedure; Laboratory Procedure
A1	Assertion T20 Negated
A2	Assertion T21 Negated
A3	Assertion T39 Negated
A5	Status T20 History_of
A4	Status T21 History_of
A6	Status T34 History_of
#34	AnnotatorNotes T5	C1709323; Open Label Study; Research Activity + C0282460; Phase 2 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity
#35	AnnotatorNotes T33	C1332166; Adenocarcinoma of the gastroesophageal junction; Neoplastic Process 
#36	AnnotatorNotes T40	C1332166; Adenocarcinoma of the gastroesophageal junction; Neoplastic Process 
#37	AnnotatorNotes T18	C0024623; Malignant neoplasm of stomach; Neoplastic Process 
#38	AnnotatorNotes T23	C0024623; Malignant neoplasm of stomach; Neoplastic Process 
#39	AnnotatorNotes T13	C0024623; Malignant neoplasm of stomach; Neoplastic Process | C5400195; Gastroesophageal junction cancer; Neoplastic Process
#40	AnnotatorNotes T15	C0278701; Gastric Adenocarcinoma; Neoplastic Process | C1332166; Adenocarcinoma of the gastroesophageal junction; Neoplastic Process
#41	AnnotatorNotes T11	C0278701; Gastric Adenocarcinoma; Neoplastic Process | C1332166; Adenocarcinoma of the gastroesophageal junction; Neoplastic Process
#42	AnnotatorNotes T3	C0278701; Gastric Adenocarcinoma; Neoplastic Process | C1332166; Adenocarcinoma of the gastroesophageal junction; Neoplastic Process
#43	AnnotatorNotes T19	C0014871; Esophagogastric Junction; Body Space or Junction 
#44	AnnotatorNotes T25	C0014871; Esophagogastric Junction; Body Space or Junction 
R1	Negation Arg1:T48 Arg2:T39	
R2	Negation Arg1:T45 Arg2:T20	
R3	Location_of Arg1:T27 Arg2:T34	
R4	Location_of Arg1:T28 Arg2:T34	
R5	Experiences Arg1:T49 Arg2:T34	
R6	Location_of Arg1:T36 Arg2:T35	
T51	Neg_cue 1228 1230	no
T52	Quantifier_or_Qualifier 1231 1241	controlada
A7	Assertion T52 Negated
R7	Negation Arg1:T51 Arg2:T52	
R8	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T52	
T53	Quantifier_or_Qualifier 1244 1257	significativa
R9	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T53	
T54	Result_or_Value 1092 1107	estado positivo
R10	Has_Result_or_Value Arg1:T26 Arg2:T54	
R11	Experiences Arg1:T47 Arg2:T26	
R12	Combined_with Arg1:T1 Arg2:T2	
R13	Experiences Arg1:T43 Arg2:T1	
R14	Location_of Arg1:T29 Arg2:T3	
R15	Location_of Arg1:T4 Arg2:T3	
R16	Experiences Arg1:T43 Arg2:T3	
#45	AnnotatorNotes T38	C4525145; Anti-LAG-3 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
R17	Combined_with Arg1:T37 Arg2:T6	
R18	Combined_with Arg1:T38 Arg2:T6	
R19	Combined_with Arg1:T37 Arg2:T7	
R20	Combined_with Arg1:T8 Arg2:T9	
R21	Used_for Arg1:T8 Arg2:T10	
R22	Used_for Arg1:T37 Arg2:T10	
R23	Experiences Arg1:T44 Arg2:T37	
R24	Experiences Arg1:T44 Arg2:T8	
R25	Experiences Arg1:T44 Arg2:T11	
R26	Location_of Arg1:T30 Arg2:T11	
R27	Location_of Arg1:T12 Arg2:T11	
R28	Location_of Arg1:T31 Arg2:T13	
R29	Location_of Arg1:T14 Arg2:T13	
R30	Location_of Arg1:T32 Arg2:T15	
R31	Location_of Arg1:T16 Arg2:T15	
T55	CONC 681 715	Eastern Cooperative Oncology Group
#46	AnnotatorNotes T55	C1520224; ECOG performance status; Intellectual Product
R32	Used_for Arg1:T55 Arg2:T46	
T56	CONC 717 721	ECOG
#47	AnnotatorNotes T56	C1520224; ECOG performance status; Intellectual Product
R33	Used_for Arg1:T56 Arg2:T46	
T57	Result_or_Value 726 731	0 o 1
R34	Has_Result_or_Value Arg1:T56 Arg2:T57	
R35	Has_Result_or_Value Arg1:T55 Arg2:T57	
R37	Before Arg1:T50 Arg2:T17	
R38	Location_of Arg1:T19 Arg2:T33	
T59	Observation 820 831	irresecable
R39	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T59	
R40	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T59	
T60	Quantifier_or_Qualifier 833 852	localmente avanzado
R41	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T60	
R42	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T60	
R43	Before Arg1:T33 Arg2:T24	
R44	Before Arg1:T18 Arg2:T24	
R45	Used_for Arg1:T21 Arg2:T20	
R46	Used_for Arg1:T21 Arg2:T22	
R47	Location_of Arg1:T25 Arg2:T40	
T61	Observation 1004 1015	irresecable
R48	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T61	
R49	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T61	
T62	Quantifier_or_Qualifier 1017 1036	localmente avanzado
R50	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T62	
R51	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T62	
R52	Before Arg1:T23 Arg2:T41	
R53	Before Arg1:T40 Arg2:T41	
#48	AnnotatorNotes T54	C1446409; Positive; Finding
R55	Experiences Arg1:T49 Arg2:T39	
R36	Negation Arg1:T45 Arg2:T21	
#49	AnnotatorNotes T20	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
#50	AnnotatorNotes T59	C4039777; Tumor surgically unresectable; Finding
#51	AnnotatorNotes T61	C4039777; Tumor surgically unresectable; Finding
#52	AnnotatorNotes T53	C1546944; Event Seriousness - Significant; Qualitative Concept
T58	Route 883 892	sistémico
R54	Has_Route_or_Mode Arg1:T21 Arg2:T58	
#53	AnnotatorNotes T58	C0205373; Systemic; Functional Concept
A8	Experiencer T49 Patient
A9	Experiencer T47 Patient
A10	Experiencer T43 Patient
A11	Experiencer T44 Patient
